IN8bio announced multiple presentations at the International Society for Cell & Gene Therapy, ISCT, 2024, to be held May 28th to June 1st in Vancouver, Canada. “ISCT is a scientific gathering renowned for fostering groundbreaking ideas and innovation in cellular therapies,” said Dr. Kate Rochlin, Chief Operating Officer of IN8bio. “Our presentations represent a significant and meaningful step in our proprietary manufacturing platform towards the advancement of gamma-delta T cell therapeutics. We will demonstrate how our manufacturing process influences cellular product characteristics and our ability to generate a robust and reproducible final product. Our DeltEx gamma-delta T cell platform has enabled the development of multiple investigational candidates which are now moving into multi-center Phase 2 clinical trials and designed to target and potentially eradicate cancer cells to help improve patient outcomes.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INAB:
- IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual Meeting
- IN8bio Announces Upcoming Presentation at 2024 European Hematology Association Congress
- IN8bio presented data on gamma-delta T cell manufacturing platform
- IN8bio price target lowered to $12.50 from $14 at H.C. Wainwright
- IN8bio reports Q1 EPS (20c), consensus (18c)